305 related articles for article (PubMed ID: 9376782)
1. Methadone maintenance and hepatitis C virus infection among injecting drug users.
Crofts N; Nigro L; Oman K; Stevenson E; Sherman J
Addiction; 1997 Aug; 92(8):999-1005. PubMed ID: 9376782
[TBL] [Abstract][Full Text] [Related]
2. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
Hallinan R; Byrne A; Amin J; Dore GJ
J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
[TBL] [Abstract][Full Text] [Related]
4. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs.
Zeiler I; Langlands T; Murray JM; Ritter A
Drug Alcohol Depend; 2010 Aug; 110(3):228-33. PubMed ID: 20430537
[TBL] [Abstract][Full Text] [Related]
5. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.
Backmund M; Reimer J; Meyer K; Gerlach JT; Zachoval R
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S330-5. PubMed ID: 15768343
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.
Chetwynd J; Brunton C; Blank M; Plumridge E; Baldwin D
N Z Med J; 1995 Sep; 108(1007):364-6. PubMed ID: 7566775
[TBL] [Abstract][Full Text] [Related]
8. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
Sheerin IG; Green FT; Sellman JD
Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
10. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
11. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
Maher L; Chant K; Jalaludin B; Sargent P
J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
[TBL] [Abstract][Full Text] [Related]
12. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C infection among drug users in northern Thailand.
Jittiwutikarn J; Thongsawat S; Suriyanon V; Maneekarn N; Celentano D; Razak MH; Srirak N; Vongchak T; Kawichai S; Thomas D; Sripaipan T; Netski D; Ananthakrishnan A; Nelson KE
Am J Trop Med Hyg; 2006 Jun; 74(6):1111-6. PubMed ID: 16760529
[TBL] [Abstract][Full Text] [Related]
14. Low risk for hepatitis C seroconversion in methadone maintenance treatment.
Peles E; Schreiber S; Rados V; Adelson M
J Addict Med; 2011 Sep; 5(3):214-20. PubMed ID: 21844836
[TBL] [Abstract][Full Text] [Related]
15. Going where the epidemic is. Epidemiology and control of hepatitis C among injecting drug users.
Crofts N
Aust Fam Physician; 2001 May; 30(5):420-5. PubMed ID: 11432013
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine injection in Melbourne, Australia--an update.
Aitken CK; Higgs PG; Hellard ME
Drug Alcohol Rev; 2008 Mar; 27(2):197-9. PubMed ID: 18264882
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus infection among a cohort of Victorian injecting drug users.
Crofts N; Hopper JL; Bowden DS; Breschkin AM; Milner R; Locarnini SA
Med J Aust; 1993 Aug; 159(4):237-41. PubMed ID: 7692222
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
[TBL] [Abstract][Full Text] [Related]
19. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination.
Carter H; Robinson G; Hanlon C; Hailwood C; Massarotto A
N Z Med J; 2001 Jul; 114(1136):324-6. PubMed ID: 11548096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
